Several oncogenic proteins and tumour suppressors target the RNA polymerase I and interfere with rRNA synthesis. Here, we show that the glycogen synthase kinase (GSK) 3b, which phosphorylates the tumour suppressor PTEN (phosphatase and tensin homologue deleted on chromosome 10), is selectively enriched in nucleoli of RAStransformed cells. Immunoprecipitation and chromatin immunoprecipitation assays performed on epithelial and endothelial cells transformed with oncogenic RAS show that GSK3b and PTEN are part of the same complex and associate with promoter and coding region of the rDNA. An active GSK3b mutant abolished nucleolar BrUTP incorporation and associated with the member of the selectivity factor 1 complex TAF I 110. Finally, GSK3b inhibition upregulated 45S, 18S and 28S rRNA synthesis in RAS-transformed epithelial cells as revealed by semiquantitative real-time PCR and promoted cellular proliferation. Our results underscore a repressive function for GSK3b in rRNA biogenesis supporting its role as a tumour supressor.
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. In proliferating cells, rRNA synthesis occurs at a higher rate presumably to accommodate increased ribosome biogenesis and protein synthesis and it is a specific target for certain tumour suppressors, which interfere with the basal pol I transcription machinery.
GSK3b was first identified as a serine kinase repressing glycogen synthesis through phosphorylation of glycogen synthase. In recent years, GSK3b has also been shown to play an important role in repression of oncogenic signalling mainly through inhibiting the stabilisation and translocation of b-catenin to the cell nucleus. In addition, expression studies indicating reduced levels of GSK3b in many tumours, the identification of GSK3b as important gatekeeper of epithelial to mesenchymal transition and its repressive role in transformation of epidermal cells have highlighted a potential function for GSK3b as tumour suppressor (Jope and Johnson, 2004; Bachelder et al., 2005; Ma et al., 2007) . Interestingly, GSK3b directly phosphorylates PTEN and both proteins are part of a negative regulatory loop, where activation of the PI3-Akt pathway leads to a repressive phosphorylation state of GSK3b (Ser9) and consequent decrease in the amount of active PTEN, which inhibits PI3 kinase (Al-Khouri et al., 2005) .
Since GSK3b and PTEN are part of the same regulatory loop and PTEN has been recently shown to repress pol I transcription by disruption of the SL1 complex (Di Cristofano et al., 1998; Chu and Tarnawski, 2004; Zhang et al., 2005) , we asked whether GSK3b plays an active part in regulating rRNA biogenesis.
To specifically investigate the potential role of GSK3b in pol I transcription, we used RAS-transformed epithelial (EpRAS) and endothelial (SVR) mouse cells (Arbiser et al., 1997; Janda et al., 2002) . These cells are known to proliferate at a higher rate in comparison with their respective parental cell lines EpH4 and MS1 and as such they represent a good model system to study rRNA biogenesis (Arbiser et al., 1997; Janda et al., 2002) . Consistently, unbiased quantification showed a 2-3-fold increase in the levels of BrUTP incorporation in EpRAS cells in comparison to non-transformed cells. Furthermore, in EpRAS and SVR cells, oncogenic H-RAS stimulates tumour angiogenesis and cooperates with transforming growth factor beta (TGF-b) during epithelial to mesenchymal transition (Arbiser et al., 1997; Janda et al., 2002) . Double immunofluorescence experiments on EpRAS and SVR cells demonstrated that PTEN and GSK3b were highly enriched in nucleoli and their distributions correlated with active pol I ( Figure 1a and Supplementary Figure 1) . In contrast, PTEN and GSK3b were not enriched in nucleoli in the corresponding parental cell lines, EpH4 (for EpRAS) and MS1 (for SVR), not transformed with oncogenic H-RAS (Figure 1a and Supplementary Figure 1) , whereas in all cases, CKII, previously shown to regulate the activity of PTEN (Torres and Pulido, 2001) , exhibited only diffuse nucleoplasmic distribution ( Figure 1a and Supplementary Figure 1) . Consistently, GSK3b and PTEN (data not shown) were also found to localize the nucleoli of fibroblasts upon tamoxifen-mediated induction of RAS expression (Supplementary Figure 2 ). GSK3b and PTEN steady state expression levels were considerably reduced in EpRAS and SVR cells in comparison to the corresponding parental cell lines (Figures 1b and c) . Finally, consistent with the presence of a highly activated form of nuclear GSK3b (Bijur and Jope, 2003) , an antibody to the inactive form of GSK3b phosphorylated on Ser9 exhibited diffuse cellular staining excluded from the cell nucleus of both EpRAS and SVR cells (Supplementary Figure 3) . Double immunofluorescence staining revealed that GSK3b and PTEN colocalize in nucleoli of EpRAS and SVR cells (Figure 2a ). Consistent with this observation, GSK3b and PTEN were also coprecipitated from total nuclear protein extracts prepared from EpRAS cells (Figure 2b ), suggesting that they may be part of the same complex. We next performed chromatin immunoprecipitation (ChIP) experiments to test whether GSK3b and PTEN are also associated with rDNA. As shown in Figure  2c , the anti-GSK3b antibody and anti-pol I autoimmune serum coprecipitated both rDNA promoter and coding region. The anti-PTEN antibody precipitated rDNA promoter and coding region only after treatment with the short-range (11 Å ), cell-permeable and thiol cleavable proteinprotein cross-linker dithiobis-succinimidyl propionate (DSP), performed before formaldehyde cross linking. Anti-GSK3b and anti-PTEN antibodies did not precipitate tRNA genes, a protein coding gene (TOPO II) (see Figure 2c) . A non-specific pig anti-rabbit immunoglobulin G did not precipitate any of the above genes, demonstrating the specificity of the ChIP assays ( Figure 2c , lane 2).
We next overexpressed active and inactive forms of GSK3b in EpRAS cells to alter GSK3b activity and to study its potential role in pol I transcription. The constitutively active GSK3b (GSK3b(Ser9Ala) cannot be phosphorylated by Akt on Ser9 (Morisco et al., 2000; Salas et al., 2003) , whereas in the inactive GSK3b, GSK3b(Lys85Arg), the ATP-binding site has been disrupted (Dominguez et al., 1995) (see Figure 3a) . The mutants were expressed in EpRAS cells by nuclear microinjection of the corresponding plasmids. After 24 hours, the levels of rRNA transcripts were monitored by BrUTP incorporation (Savino et al., 1999) , using a monoclonal anti-BrUTP antibody and confocal Immunofluorescence and confocal microscopy were performed as described using a LSM 510 Laser Scanning Microscope (Zeiss, Germany) (Percipalle et al., 2006) . (b) Steady state expression levels of PTEN and GSK3b in EpRAS, SVR and parental cell lines, EpH4 and MS1 (cf. lanes 1 and 4). Expression levels were detected on immunoblots of total cell lysates immunostained with an anti-PTEN and an anti-GSK3b antibody. Protein levels were normalized against the expression of endogenous b-actin using monoclonal antibody AC-74 (Sigma-Aldrich Sweden AB, Stockholm, Sweden). Detection was by ECL (GE Healthcare, Europe, Uppsala, Sweden) using horse radish peroxidase (HRP)-conjugated secondary antibodies (DAKO, Denmark). (c) The bar diagram shows the quantification of the steady state expression levels of PTEN and GSK3b relative to actin. EpRAS, RAS-transformed epithelial; GSK, glycogen synthase kinase; PTEN, phosphatase and tensin homologue deleted on chromosome 10.
GSK3b in Pol I transcription T Vincent et al microscopy. Expression of the active GSK3b caused a considerable decrease in the amount of BrUTP incorporated in elongating rRNA transcripts (Figure 3b ). In contrast, expression of the inactive GSK3b did not affect BrUTP incorporation (Figure 3b) . Given that the nucleolar distribution of GSK3b is sensitive to transcription inactivation ( Supplementary  Figure 4) , our results underscore a potential repressive function of GSK3b in rRNA synthesis.
To examine GSK3b association with pol I-specific transcription factors, we expressed an HA-tagged version of active GSK3b in EpRAS cells (Figure 3c , cf. lanes 1 and 2). After protein-protein DSP crosslinking, total nuclear extracts were subjected to immunoprecipitations with an anti-HA tag antibody or with an anti-PTEN antibody. The blots in Figure 3d show that active GSK3b could precipitate SL1/TAF I 110 from cross-linked cells, whereas it did not precipitate active pol I (cf. lanes 2 and 3). Consistent with previous observations (Zhang et al., 2005) , a monoclonal anti-PTEN antibody coprecipitated low levels of SL1/TAF I 110 and did not coprecipitate pol I from the same EpRAS cells expressing active GSK3b (Figure 3d, cf. lanes 4 and 5) . A non-specific pig anti-rabbit immunoglobulin G did not coprecipitate SL1/TAF I 110 and pol I (Figure 3d, cf. lanes 6 and 7) , supporting the specificity of the immunoprecipitations. We conclude that active GSK3b associates with SL1/TAF I 110.
The activity of GSK3b can be specifically inhibited in cells with the cell permeable organic compound 6-bromoindirubin-3 0 -oxime (BIO), which has been cocrystallized with GSK3b and is known to promote cellular proliferation in cardiomyocytes (Meijer et al., 2006; Tseng et al., 2006) . Treatment with BIO caused GSK3b redistribution in EpRAS cells but not in the parental EpH4 cell lines (see Supplementary Figure 5 ). Under these conditions, it is known that the steady state protein expression levels of GSK3b remain constant, whereas the level of the active, endogenous Tyr216-phosphorylated GSK3b is considerably decreased (Meijer et al., 2006) . Therefore, we incubated EpRAS cells with BIO and analysed the levels of 45S pre-rRNA, 18S, 28S rRNAs and a tRNA species by semiquantitative realtime PCR. The experiments repeated in triplicates were normalized with respect to the endogenous b-actin gene and glyceraldehyde 3-phosphate dehydrogenase (GADPH) gene. Overall, the steady state levels of 45S pre-rRNA, 28S and 18S rRNAs were all significantly increased (Figure 4a ). In view of the above results, we next evaluated the potential role of GSK3b on cellular proliferation. Upon GSK3b inhibition with BIO, we revealed a considerable twofold increase in the number of EpRAS cells, as revealed by direct cell counting (Figure 4b ). In addition, GSK3b inhibition resulted in a significant increase in the amount of BrdU incorporation consistent with increased rate of DNA replication (see Figure 4c ). Cell cycle profiles revealed a 40% increase in the number of cells in S-and G2/M phases as a consequence of GSK3b inhibition, presumably through elevated rates of G1 to S-phase transitions (see Figure 4d) . Finally, no effects were observed on the levels of apoptotic cells (not shown). We conclude that GSK3b represses rRNA synthesis and cellular proliferation.
A negative regulatory role in cell growth and proliferation has been proposed for GSK3b (Leslie and Downes, 2004) . While downregulating the ERK1/2 signalling pathway, GSK3 also affects the RAS/RAF/MEK-I pathway (Wang et al., 2006) . Our results suggest that this negative role may be performed by GSK3b through a repressive action on rRNA biogenesis.
The highly activated nuclear GSK3b (Bijur and Jope, 2003) Immunoprecipitations were performed with anti-GSK3b and anti-PTEN antibodies as well as with a non-specific immunoglobulin G (DIANOVA), as described in (Percipalle et al., 2006) . In nuclear extracts and immunoprecipitated fractions, endogenous GSK3b and PTEN were detected on immunoblots. (c) PTEN and GSK3b associate with rDNA promoter and coding region. Chromatin immunoprecipitation (ChIP) analysis was performed as described (Percipalle et al., 2006) . For the extra cross-linking step, cells were treated with 0.5 mM DSP (Sigma-Aldrich, USA) for 20 min at 37 1C (Percipalle et al., 2006) , before formaldehyde cross-linking. After elution and reversion of protein-DNA cross-links by overnight heating at 65 1C, DNA-protein complexes were treated with proteinase K and precipitated with ethanol. Primers sequences are available upon request. All ChIP experiments were performed in duplicates. DSP, dithiobis-succinimidyl propionate; EpRAS, RAS-transformed epithelial; GSK, glycogen synthase kinase; PTEN, phosphatase and tensin homologue deleted on chromosome 10.
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GSK3b and PTEN are at the rDNA promoter. In this scenario, GSK3b and PTEN may be part of a nuclear regulatory loop (Baker, 2007) , which represses pol I transcription by disrupting the SL1 complex. The presence of GSK3b and PTEN on the gene coding region and the inhibitory role of GSK3b on the biogenesis of 28S and 18S
rRNAs, also suggest a role in the late transcription phases, presumably coupled to rRNA processing and pre-ribosome assembly. Aberrant ribosome biogenesis and disruption of transcriptional control contribute to cellular proliferation and transformation. Our observations support the proposed function for GSK3b as tumour . After 24 h expression at 37 1C, injected and mock-injected (empty plasmid) EpRAS cells were subjected to run-on assay by 5-bromouridine 5 0 -triphosphate (BrUTP) incorporation to monitor pol I transcription (Savino et al., 1999) . BrUTP incorporation into newly synthesized rRNA transcripts was monitored by immunofluorescence labelling with a mouse anti-BrUTP monoclonal antibody (Roche) and analysed by confocal microscopy (scale bar 10 mM). More than 75% of cells (approximately 300) expressing active GSK3b, showed decreased BrUTP incorporation. (c) For hemagglutinin (HA)-tagged GSK3b(Ser9Ala) expression, EpRAS cells were transfected with Fugene (Roche, Switzerland) and total lysates monitored on immunoblots with a monoclonal anti-HA tag antibody (BioSite, San Diego, CA, USA). (d) Active GSK3b and SLI/transcription factor (TAF I 110) associate in living cells. After DSP cross-linking (Percipalle et al., 2006) , immunoprecipitations were performed from nuclear extracts with anti-HA tag and anti-PTEN antibodies and a non specific immunoglobulin G (DIANOVA), as described (Percipalle et al., 2006) . In the immunoprecipitated fractions, endogenous SL1/ TAF I 110 was detected on immunoblots with a polyclonal antibody to TAF I 110 (Seither and Grummt, 1996) , whereas pol I was revealed with a human autoimmune serum (Percipalle et al., 2006) . DSP, dithiobis-succinimidyl propionate; EpRAS, RAStransformed epithelial; GSK, glycogen synthase kinase; pol 1, polymerase I; PTEN, phosphatase and tensin homologue deleted on chromosome 10; SL1, selectivity factor 1.
GSK3b in Pol I transcription T Vincent et al suppressor (Jope and Johnson, 2004) and suggest that the molecular mechanisms counteracting highly proliferating states induced by oncogenes such as H-RAS involve GSK3b and PTEN to inhibit pol I transcription and cellular proliferation.
